Rocky Mountain Cancer Centers

Recent papers from Rocky Mountain Cancer Centers

1. Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort StudyeJHaem · 2026
2. Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi studyFuture Oncology · 2026
3. Outpatient venetoclax initiation following obinutuzumab debulking in patients with high or medium tumor burden at baselineLeukemia & lymphoma/Leukemia and lymphoma · 2026
4. Integrating ctDNA-Based ESR1 m Monitoring Into First-Line Care for ER+, HER2– Advanced Breast Cancer: A Consensus WorkflowThe Oncologist · 2026
5. Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell LymphomaBlood Advances · 2026
6. Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
7. Posterior Circulation Stroke After Subclavian Artery Thrombosis Following Low-Voltage Electrical Injury in an Active Woman With Previously Unrecognized Prothrombotic Risk Factors: A Case ReportCureus · 2026
8. Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaAdvances in Therapy · 2026
9. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summaryFuture Oncology · 2026
10. Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaHaematologica · 2026
11. TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisBlood · 2026
12. Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP– but not Pola-R-CHP–treated patients with DLBCLBlood Neoplasia · 2026
13. Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.Journal of Clinical Oncology · 2026
14. frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).Journal of Clinical Oncology · 2026
15. Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.Journal of Clinical Oncology · 2026
16. Real-world characteristics, treatment patterns, and outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients treated in first-line (1L) in the United States (US) community oncology setting.Journal of Clinical Oncology · 2026
17. Phase II study of cemiplimab ± fianlimab following SBRT for oligometastatic clear-cell RCC (LAG-BOOST).Journal of Clinical Oncology · 2026
18. EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).Journal of Clinical Oncology · 2026
19. The effect of automated quantitative evaluation of lesion response heterogeneity in patients with metastatic neuroendocrine tumors.Journal of Clinical Oncology · 2026
20. Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid.Journal of Clinical Oncology · 2026